Location: Jacksonville (Headquarters)

3550 University Blvd South

Suite #101

Jacksonville, FL 32216

Tel: (904) 854-1354

Fax:

Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Jacksonville - Southside, Lake City, St. Augustine

Condition: Heart Disease, High Cholesterol

Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk

Location(s): Jacksonville (Headquarters), Jacksonville - Southside, Lake City, Macon, St. Augustine

Condition: Heart Disease, High Cholesterol

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Jacksonville - Southside, Lake City, Macon

Condition: Diabetes, Kidney Disease

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

Location(s): Jacksonville (Headquarters)

Condition: Diabetes, Overweight/Obesity

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a).

Location(s): Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), St. Augustine

Condition: Heart Disease

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, Southside, St. Augustine

Condition: Heart Disease

Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation

Location(s): Jacksonville (Headquarters)

Condition: Heart Disease, Kidney Disease

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Location(s): Jacksonville (Headquarters), St. Augustine

Condition: Heart Failure